Sumatriptan, a selective 5-HT1B/1D receptor agonist, rapidly alleviates cluster headache symptoms by causing vasoconstriction and inhibiting neuropeptide release in cerebral blood vessels. When administered subcutaneously, it provides quick relief by reducing inflammation and interrupting the trigeminovascular pain pathway, with onset of action typically within 10-15 minutes and peak efficacy occurring shortly thereafter.